Magnetic Resonance Lung Function Imaging Study of Pulmonary Fibrosis Combined With Emphysema Syndrome
Launched by BEIJING CHAO YANG HOSPITAL · May 22, 2024
Trial Information
Current as of November 09, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new way to look at lung function in patients with a condition called Combined Pulmonary Fibrosis and Emphysema Syndrome (CPFE). Researchers are using a special type of imaging called magnetic resonance imaging (MRI) to see how blood flow in the lungs changes over time. By examining patients at the start of the study, and again after 6 and 12 months, the team hopes to find early signs of lung problems that could help with diagnosis and treatment.
To participate in this trial, individuals need to meet certain criteria. They should have imaging results showing emphysema primarily in the upper lungs and pulmonary fibrosis in the lower lungs. Those interested should also be able to undergo an MRI without any issues, like having a pacemaker or feeling claustrophobic. Participants will undergo MRI scans at the designated times, and their experiences will help researchers learn more about how these lung diseases progress. This study is currently recruiting patients of all ages and genders who meet the eligibility criteria.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • (1) Chest HRCT shows emphysema mainly distributed in the upper lung field, manifesting as wallless or thin-walled (wall thickness \<1 mm) low-transmittance areas with clear boundaries with normal tissue, or multiple bullae (diameter \> 1 cm), and the emphysema area/total lung volume is ≥10%; (2) interstitial pulmonary fibrosis mainly distributed in the lower lung field and subpleura, manifesting as honeycomb shadow or grid shadow, and the lung structure is destroyed , may be accompanied by traction bronchiectasis, ground glass opacities and consolidation opacities.
- Exclusion Criteria:
- • (1) Refusal to sign the informed consent form; (2) MRI contraindications (implanted pacemaker/defibrillator, claustrophobia, or any clinical condition that prohibits longer MRI examinations).
About Beijing Chao Yang Hospital
Beijing Chao Yang Hospital, a leading medical institution in China, is dedicated to advancing healthcare through innovative clinical research and trials. Affiliated with the Capital Medical University, the hospital boasts a multidisciplinary team of experienced healthcare professionals and researchers committed to improving patient outcomes. With a focus on evidence-based medicine, Beijing Chao Yang Hospital actively engages in diverse clinical studies across various therapeutic areas, aiming to contribute to the global medical community and enhance the standard of care through rigorous scientific inquiry.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Beijing, Beijing, China
Patients applied
Trial Officials
Shumin Wang, PhD
Study Director
Beijing Chao Yang Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported